97144 ⎘
Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
VACCINE CONTAINING RBD2 OF CDTB COMPONENT FROM BINARY TOXIN CDT OF CLOSTRIDIOIDES DIFFICILE
#2Antibodies to Botulinum Neurotoxins
#3PEPTIDE CONSTRUCT HAVING A PROTEASE-CLEAVABLE LINKER
#4EPSILON TOXIN FROM CLOSTRIDIUM PERFRINGENS AS A VACCINE
#5SINGLE DOMAIN ANTIBODIES FOR PREVENTION OF CLOSTRIDIUM DIFFICILE INFECTION
#6ISOLATED POLYPEPTIDE OF THE TOXIN A AND TOXIN B PROTEINS OF C. DIFFICILE AND USES THEREOF
#7COMPOSITIONS AND METHODS FOR ELICITING AN IMMUNE RESPONSE AGAINST CLOSTRIDIUM DIFFICILE
#8ENGINEERED POLYPEPTIDES AND USES THEREOF
#9Antibodies to Botulinum Neurotoxins
#10ANTIBODIES TO NECROTIC ENTERITIS B-LIKE TOXIN
#11ANTIBODY BINDING TO CLOSTRIDIUM DIFFICILE
#12NANOBODIES FOR TREATING C. DIFFICILE INFECTION
#13ANTI-PCSK9 ANTIBODIES
#14ANTIBODIES BINDING TO TETANUS TOXIN AND USES THEREOF
#15ANTIBODY FOR TETANUS TOXIN AND USE THEREOF
#16METHODS, COMPOSITIONS AND KITS FOR TREATING A SUBJECT USING A RECOMBINANT HETEROMULTIMERIC NEUTRALIZING BINDING PROTEIN
#17LINKABLE SINGLE DOMAIN ANTIBODIES THAT COVALENTLY BIND TO A TARGET ANTIGEN AND METHODS OF USE THEREOF
#18COMPOSITION CONTAINING MONOCLONAL ANTIBODY
#19CELL-BASED METHOD FOR DETERMINING AN ACTIVITY OF BOTULINUM TOXIN
#20VHH BASED BINDING ANTIBODIES FOR ANTHRAX AND BOTULINUM TOXINS AND METHODS OF MAKING AND USING THEREFOR
#21VHH POLYPEPTIDES THAT BIND TO CLOSTRIDIUM DIFFICILE TOXIN B AND METHODS OF USE THEREOF
#22ANTIBODIES AGAINST DISEASE CAUSING AGENTS OF POULTRY AND USES THEREOF
#23CHIMERIC SECRETORY COMPONENT POLYPEPTIDES AND USES THEREOF
#24MONOCLONAL ANTIBODY-CONTAINING COMPOSITION FOR SUPPRESSING CLOSTRIDIUM DIFFICILE BACTERIA
#25MODIFIED KAPPA LIGHT CHAIN-BINDING POLYPEPTIDES
#26Tetanus prophylaxis
#27METHODS AND MEANS FOR THE PRODUCTION OF IG-LIKE MOLECULES
#28GENETICALLY-MODIFIED SACCHAROMYCES YEAST STRAINS AS PREVENTATIVE AND THERAPEUTIC AGENTS
#29MUCOSAL EXPRESSION OF ANTIBODY STRUCTURES AND ISOTYPES BY MRNA
#30METHOD OF PRODUCING ANTIBODIES FROM SINGLE PLASMA CELLS
#31CELL-BASED METHOD FOR DETERMINING AN ACTIVITY OF BOTULINUM TOXIN
#32SYSTEMS AND METHODS TO LINK CD40 SIGNALING TO ANTIGEN BINDING
#33COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNODEFICIENCY
#34COMPOSITIONS RELATING TO A MUTANT CLOSTRIDIUM DIFFICILE TOXIN AND METHODS THEREOF
#35Methods and means for the production of Ig-like molecules
#36Anti-PCSK9 antibodies
#37YEAST-BASED IMMUNOTHERAPY AGAINST CLOSTRIDIUM DIFFICILE INFECTION
#38CELLS USEFUL FOR IMMUNO-BASED BOTULINUM TOXIN SEROTYPE A ACTIVITY ASSAYS
#39RNA ENCODING AN ANTIBODY
#40DEVICE, PROCEDURE AND SYSTEM FOR DETECTING BACTERIAL PATHOGENS INCLUDING METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS OR CLOSTRIDIUM DIFFICILE
#41ANTIBODIES TO BOTULINUM NEUROTOXINS
#42IMMUNO-BASED BOTULINUM TOXIN SEROTYPE A ACTIVITY ASSAYS
#43SYSTEMS AND METHODS TO PRODUCE B CELLS GENETICALLY MODIFIED TO EXPRESS SELECTED ANTIBODIES
#44IMMUNO-BASED BOTULINUM TOXIN SEROTYPE A ACTIVITY ASSAYS
#45IMMUNOGENIC COMPOSITIONS AGAINST CLOSTRIDIOIDES (CLOSTRIDIUM) DIFFICILE AND METHODS THEREOF
#46VHH polypeptides that bind to toxin b and methods of use thereof
#47ISOLATED POLYPEPTIDE OF THE TOXIN A AND TOXIN B PROTEINS OF C. DIFFICILE AND USES THEREOF
#48CLOSTRIDIUM DIFFICILE ANTIGENS
#49Method for the treatment or prevention of infection-related immune conditions using a composition comprising IgM
#50Compositions and methods for the treatment of immunodeficiency
#51A COMBINATION OF PLASMA IMMUNOGLOBULIN AND ANTIGEN-SPECIFIC IMMUNOGLOBULIN FOR THE MODIFICATION OF THE IMMUNE SYSTEM AND THE TREATMENT OR PREVENTION OF AUTOIMMUNE DISEASES
#52Single domain antibodies binding to tetanus neurotoxin
#53Antibodies for Botulinum Neurotoxins
#54Humanized tetra-specific octavalent antibody against clostridium difficile toxin A and B
#55VACCINE AGAINST NECROTIC ENTERITIS IN POULTRY
#56COMPOSITIONS AND METHODS FOR ELICITING AN IMMUNE RESPONSE AGAINST CLOSTRIDIUM DIFFICILE
#57IMMUNO-BASED BOTULINUM TOXIN SEROTYPE A ACTIVITY ASSAYS
#58EPITOPES OF CLOSTRIDIUM DIFFICILE TOXINS A AND B AND USES THEREOF
#59A GENETICALLY MODIFIED LACTOBACILLUS AND USES THEREOF
#60PROBIOTIC COMPOSITIONS COMPRISING LACTOBACILLUS REUTERI STRAINS AND METHODS OF USE
#61CELLULAR VAMP CLEAVAGE ASSAY
#62Antibodies for Botulinum Neurotoxins
#63Antibodies against clostridium difficile toxins and methods of using the same
#64Method for isolation of soluble polypeptides
#65CELL-BASED METHOD FOR DETERMINING AN ACTIVITY OF BOTULINUM TOXIN
#66BI-SPECIFIC CONJUGATES
#67Isolated polypeptide of the toxin A and toxin B proteins of and uses thereof
#68CLOSTRIDIUM DIFFICILE ANTIGENS
#69Methods, compositions and kits for treating a subject using a recombinant heteromultimeric neutralizing binding protein
#70VACCINE AND ANTIBODY AGAINST CLOSTRIDIOIDES DIFFICILE TOXIN
#71Immuno-based botulinum toxin serotype A activity assays
#72Polypeptides
#73ANTIBODIES AGAINST DISEASE CAUSING AGENTS OF POULTRY AND USES THEREOF
#74ANTIBODIES AGAINST CLOSTRIDIUM DIFFICILE TOXINS AND USES THEREOF
#75Methods for detection of botulinum neurotoxin
#76ANTI-PCSK9 ANTIBODIES
#77VHH based binding antibodies for anthrax and botulinum toxins and methods of making and using therefor
#78TREATMENT OF IMMUNE DISEASES BY MEANS OF THE ANTIBODY-MEDIATED NEUTRALIZATION OF SPECIFIC INTESTINAL BACTERIA
#79Peptide construct having a protease-cleavable linker
#80Systems and methods to produce B cells genetically modified to express selected antibodies
#81HETEROMULTIMERIC BINDING MOLECULES FOR TOXIN NEUTRALIZATION, COMPOSITIONS AND METHODS THEREOF
#82Immuno-based botulinum toxin serotype A activity assays
#83CLOSTRIDIUM DIFFICILE-SPECIFIC ANTIBODIES AND USES THEREOF
#84Compositions and methods for the treatment of immunodeficiency
#85Isolated polypeptide of the toxin A and toxin B proteins of and uses thereof
#86Means and methods for the determination of the biological activity of BoNT/E in cells
#87Basehit, a high-throughput assay to identify proteins involved in host-microbe interaction
#88Methods and means for the production of Ig-like molecules
#89Cell-based method for determining an activity of botulinum toxin
#90Human neutralizing anti-tetanus toxin monoclonal antibody and its applications
#91Epsilon toxin from clostridium perfringens as a vaccine
#92IMMUNO-BASED BOTULINUM TOXIN SEROTYPE A ACTIVITY ASSAYS
#93NEUTRALISING ANTIBODIES TO THE MAJOR EXOTOXINS TCDA AND TCDB OF CLOSTRIDIUM DIFFICILE
#94IMMUNO-BASED BOTULINUM TOXIN SEROTYPE A ACTIVITY ASSAYS
#95Cell-based method for determining an activity of botulinum toxin
#96Cell-based method for determining an activity of botulinum toxin
#97Cell-based method for determining an activity of botulinum toxin
#98Antibodies for botulinum neurotoxins
#99ANTIBODIES WITH FUNCTIONAL DOMAINS IN THE ELBOW REGION BETWEEN VARIABLE AND CONSTANT DOMAIN
#100COMPOSITIONS AND METHODS FOR TREATMENT IN BROAD-SPECTRUM, UNDIFFERENTIATED OR MIXED CLINICAL APPLICATIONS
#101ENGINEERED POLYPEPTIDES AND USES THEREOF
#102GENERATION OF HEAVY-CHAIN ONLY ANTIBODIES IN TRANSGENIC ANIMALS
#103Delivery of structurally diverse polypeptide cargo into mammalian cells by a bacterial toxin
#104METHOD FOR THE TREATMENT OR PREVENTION OF INFECTION-RELATED IMMUNE CONDITIONS USING A COMPOSITION COMPRISING IGM
#105Method for treating infectious diseases using a composition comprising plasma-derived immunoglobulin M (IgM)
#106PRODUCTION OF ENUCLEATED RED BLOOD CELLS AND USES THEREOF
#107Cell-based method for determining an activity of botulinum toxin
#108Compositions for the treatment of disease
#109Compositions relating to a mutant clostridium difficile toxin and methods thereof
#110Vaccine against necrotic enteritis in poultry
#111CLOSTRIDIUM DIFFICILE TOXINS A AND/OR B ANTIGEN AND EPITOPE ANTIBODY, AND PHARMACEUTICAL USES THEREOF
#112RNA encoding an antibody
#113Human genetic markers associated with response to treatments that target clostridium difficile toxin B
#114Methods and means for the production of ig-like molecules
#115Hyperimmunized egg product for treatment of necrotic enteritis in poultry
#116Antibodies that neutralize botulinum neurotoxins
#117RECOMBINANT EXPRESSION SYSTEMS AND PRODUCTS
#118Method for the treatment or prevention of infection-related immune conditions using a composition comprising IgM
#119CLOSTRIDIUM DIFFICILE ANTIGENS
#120UNIVERSAL PLATFORM FOR TARGETING THERAPIES TO TREAT NEUROLOGICAL DISEASES
#121Isolated polypeptide of the toxin A and toxin B proteins of and uses thereof
#122THERAPY FOR ENTERIC INFECTIONS
#123Antibodies to botulinum neurotoxins
#124Anti-PD-L1-anti-TIM-3 bispecific antibodies
#125Methods, compositions and kits for treating a subject using a recombinant neutralizing binding protein
#126Cellular vamp cleavage assay
#127Compositions relating to a mutant clostridium difficile toxin and methods thereof
#128Antibodies against toxins and methods of using the same
#129Anti-PCSK9 antibodies
#130Therapy of multiple organ system failure by anti-toxin antibodies and prophylaxis by anaerobic toxoids
#131MICROPARTICULATE SYSTEM FOR COLONIC DRUG DELIVERY
#132Method for isolation of soluble polypeptides
#133Compositions and methods for inhibiting Wnt signaling
#134Means and methods for the determination of the biological activity of BoNT/E in cells
#135Use of polyclonal antibodies against clostridium difficile for treatment of inflammatory bowel disease
#136MONOCLONAL ANTIBODY PRODUCTION BY EBV TRANSFORMATION OF B CELLS
#137Yeast-based immunotherapy against clostridium difficile infection
#138Anti-PD-L1-anti-TIM-3 bispecific antibodies
#139Compositions and methods for the treatment of immunodeficiency
#140Tetra-specific, octameric binding agents and antibodies against toxin A and toxin B for treatment of infection
#141Single chain antibody domains for detection of anti-botulinum neurotoxin domains and methods of their use
#142Hyperimmunized egg product for treatment of necrotic enteritis in poultry
#143Antibodies for botulinum neurotoxins
#144Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
#145ANTIBODIES AGAINST CLOSTRIDIUM DIFFICILE TOXINS AND USES THEREOF
#146THERAPY FOR ENTERIC INFECTIONS
#147ANTIBODY PRODUCING NON-HUMAN ANIMALS
#148ANTIBODY PRODUCING NON-HUMAN ANIMALS
#149Antibody producing non-human animals
#150ANTIBODY PRODUCING NON-HUMAN ANIMALS
#151Antibody producing non-human animals
#152Antibody producing non-human animals
#153CLOSTRIDIUM DIFFICILE-SPECIFIC ANTIBODIES AND USES THEREOF
#154POLYPEPTIDE COMPRISING AN IMMUNOGLOBULIN CHAIN VARIABLE DOMAIN WHICH BINDS TO CLOSTRIDIUM DIFFICILE TOXIN A
#155POLYPEPTIDE COMPRISING AN IMMUNOGLOBULIN CHAIN VARIABLE DOMAIN WHICH BINDS TO CLOSTRIDIUM DIFFICILE TOXIN B
#156Compositions and methods for the treatment of immunodeficiency
#157METHODS FOR TREATING CLOSTRIDIUM DIFFICILE INFECTION AND ASSOCIATED DISEASE
#158Delivery of structurally diverse polypeptide cargo into mammalian cells by a bacterial toxin
#159PEPTIDE CONSTRUCT HAVING A PROTEASE-CLEAVABLE LINKER
#160Engineered polypeptides and uses thereof
#161Immunoassays for differential detection of clostridium difficile
#162Clostridium difficile toxins a and/or B antigen and epitope antibody, and pharmaceutical uses thereof
#163POLYPEPTIDES
#164Methods and means for the production of Ig-like molecules
#165VHH based binding antibodies for anthrax and botulinum toxins and methods of making and using therefor
#166Nucleotide sequences, vectors and host cells
#167Methods and means for the production of Ig-like molecules
#168Compositions and methods for treatment in broad-spectrum, undifferentiated or mixed clinical applications
#169SYSTEM FOR PRODUCTION OF ANTIBODIES AND THEIR DERIVATIVES
#170Compositions relating to a mutant toxin and methods thereof
#171Immuno-based botulinum toxin serotype A activity assays
#172UNIVERSAL PLATFORM FOR TARGETING THERAPIES TO TREAT NEUROLOGICAL DISEASES
#173Method for purification of monoclonal antibodies
#174Use of an agent consisting of antibodies and/or insulin-like growth factor antagonists
#175Nucleotide sequences, vectors and host cells
#176Isolated polypeptide of the toxin A and toxin B proteins of and uses thereof
#177Methods, compositions and kits for treating a subject using a recombinant heteromultimeric neutralizing binding protein
#178Antibodies that neutralize botulinum neurotoxins
#179ANIMAL MODELS AND THERAPEUTIC MOLECULES - Track 1
#180Neurotoxins exhibiting shortened biological activity
#181Oligosialic acid derivatives, methods of manufacture, and immunological uses
#182Clostridium difficile antibodies
#183Method for treating infectious diseases using a composition comprising plasma-derived immunoglobulin M (IgM)
#184Method for the treatment or prevention of infection-related immune conditions using a composition comprising IgM
#185Therapeutic peptides
#186Methods, compositions and kits for treating a subject using a recombinant neutralizing binding protein
#187IgA multi-specific binding molecules
#188Methods, compositions and kits for treating a subject using a recombinant heteromultimeric neutralizing binding protein
#189Antibody that specifically binds partially processed or unprocessed neurotoxin polypeptides
#190Peptide core-based multi-arm linkers for treating infectious diseases
#191CLOSTRIDIUM DIFFICILE VACCINE
#192Treatment of celiac disease, C. difficile infection, food intolerance and food allergy with secretory IgA/IgM
#193antigens
#194Generation of heavy-chain only antibodies in transgenic animals
#195HUMAN ANTIBODIES TO CLOSTRIDIUM DIFFICILE TOXINS
#196Animal models and therapeutic molecules
#197Antibodies for botulinum neurotoxins
#198Protein drug formulations and packages
#199Methods and means for the production of Ig-like molecules
#200Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
#201Clostridium Difficile Compositions and Methods of Use
#202Nucleotide sequences, vectors and host cells
#203Propeptide fusion comprising a mutated clostridium botulinum neurotoxin and a VHH domain
#204ANTIBODIES AGAINST CLOSTRIDIUM DIFFICILE TOXINS AND USES THEREOF
#205Antibodies for prevention and treatment of diseases caused by clostridium difficile
#206Compositions and methods for the treatment of immunodeficiency
#207Compositions and methods for the treatment of immunodeficiency
#208Methods and compositions for the treatment and/or prophylaxis of associated disease
#209Clostridium difficile vaccine and methods of use
#210Antibodies against toxins and methods of using the same
#211Method for isolation of soluble polypeptides
#212Toxins in type A
#213Methods and compositions with a recombinant neutralizing binding protein for treating toxin exposure
#214Neurotoxins exhibiting shortened biological activity
#215Methods to protect against and treat multiple sclerosis
#216Polyclonal antibodies against and uses thereof
#217Clostridium difficile polypeptides as vaccine
#218Antibodies against
#219Designer Ubiquitin Ligases for Regulation of Intracellular Pathogenic Proteins
#220HUMAN ANTIBODY SPECIFIC TO TOXIN PRODUCED FROM CLOSTRIDIUM DIFFICILE, OR ANTIGEN-BINDING FRAGMENT THEREOF
#221Antibodies that neutralize botulinum neurotoxins
#222METHODS AND MEANS FOR THE PRODUCTION OF IG-LIKE MOLECULES
#223ANTIBODIES FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE-ASSOCIATED INFECTION AND DISEASE
#224Secretory immunoglobulin complex
#225Toxin in type A
#226High-affinity monoclonal antibodies for botulinum toxin type B
#227Compositions relating to a mutant toxin and methods thereof
#228Anti-C. difficile toxin antibodies and associated methods
#229Methods and systems for multi-antibody therapies
#230PROCESS FOR THE PREPARATION AND USE OF A BIVALENT VACCINE AGAINST MORPHINE-HEROIN ADDICTION
#231Epsilon toxin epitopes from with reduced toxicity
#232Isolated polypeptide of the toxin A and toxin B proteins of and uses thereof
#233IMMUNIZATION AGAINST CLOSTRIDIUM DIFFICILE DISEASE
#234Antibodies for botulinum neurotoxins
#235Prevention of infection
#236ANTIBODIES TO CLOSTRIDIUM DIFFICILE TOXINS
#237Methods of Identifying a Compound that Increases or Decreases the Interaction of Hn-33 with Synaptotagmin II
#238Rationally designed antibodies
#239System for determining unprocessed and partially processed neurotoxin type A
#240Neutralising antibodies to the major exotoxins TCDA and TCDB of
#241Antibody producing non-human mammals
#242Antibody producing non-human mammals
#243Methods and compositions with a recombinant neutralizing binding protein for treating toxin exposure
#244Engineered type IV pilin of
#245System for production of antibodies and their derivatives
#246Oligosaccharides and oligosaccharide-protein conjugates derived from polysaccharide PS-I, methods of synthesis and uses thereof, in particular as vaccines and diagnostic tools
#247Clostridial neurotoxins with altered persistency
#248Immunogenic composition
#249Pathogenic bacteria
#250Methods and means for the production of IG-like molecules
#251CLOSTRIDIUM DIFFICILE ANTIGENS
#252Antibodies against clostridium difficile toxins and uses thereof
#253Use of an agent consisting of antibodies and/or insulin-like growth factor antagonists
#254Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
#255Immunogenic composition
#256Methods and means for the production of Ig-like molecules
#257Neurotoxins exhibiting shortened biological activity
#258Compositions against bacterial toxins
#259Monoclonal antibody production by EBV transformation of B cells
#260antibodies
#261Therapeutic peptides
#262OLIGOSACCHARIDES AND OLIGOSACCHARIDE-PROTEIN CONJUGATES DERIVED FROM CLOSTRIDIUM DIFFICILE POLYSACCHARIDE PS-II, METHODS OF SYNTHESIS AND USES THEREOF, IN PARTICULAR AS A VACCINE
#263Engineered type IV pilin of
#264Methods and means for the production of Ig-like molecules
#265Compositions relating to a mutant toxin and methods thereof
#266Medicament for LCT poisoning
#267antigens
#268-specific antibodies and uses thereof
#269Human antibodies to toxins
#270Antibodies for the treatment of -associated infection and disease
#271Immunization against disease
#272Antibody producing non-human mammals
#273Peptides, conjugates and method for increasing immunogenicity of a vaccine
#274Methods, compositions and kits for treating a subject using a recombinant heteromultimeric neutralizing binding protein
#275PROTEIN DRUG FORMULATIONS AND PACKAGES
#276IMMUNO-BASED BOTULINUM TOXIN SEROTYPE A ACTIVITY ASSAYS
#277Method for Cloning Cognate Antibodies
#278Therapies for preventing or suppressing infection
#279Antibodies against clostridium difficile toxins and uses thereof
#280TARGETING OF THE C-TERMINAL SEGMENT OF C.DIFFICILE TOXIN B FOR IMPROVED CLINICAL DIAGNOSIS, PREVENTION, AND TREATMENT
#281Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
#282Compositions relating to a mutant toxin and methods thereof
#283Anti-Botulinum Neurotoxin a Single Domain Antibody Antibodies
#284Immuno-based botulinum toxin serotype A activity assays
#285Cells useful for immuno-based botulinum toxin serotype A activity assays
#286Cells useful for immuno-based botulinum toxin serotype A activity assays
#287System for determining unprocessed and partially processed neurotoxin type A
#288Cells useful for immuno-based botulinum toxin serotype A activity assays
#289Cells useful for immuno-based botulinum toxin serotype A activity assays
#290Therapeutic Monoclonal Antibodies that Neutralize Botulinum Neurotoxins
#291THERAPY FOR ENTERIC INFECTIONS
#292Cells useful for immuno-based botulinum toxin serotype A activity assays
#293Cells useful for immuno-based botulinum toxin serotype A activity assays
#294Cells useful for immuno-based botulinum toxin serotype A activity assays
#295Cells useful for immuno-based botulinum toxin serotype A activity assays
#296Cells useful for immuno-based Botulinum toxin serotype A activity assays
#297Cells useful for immuno-based botulinum toxin serotype A activity assays
#298Cells Useful for Immuno-Based Botulinum Toxin Serotype A Activity Assays
#299Cells useful for immuno-based botulinum toxin serotype A activity assays
#300Cells Useful for Immuno-Based Botulinum Toxin Serotype A Activity Assays